Trevi Therapeutics (TRVI) Capital Expenditures (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Capital Expenditures of $102000.0 for Q1 2026, up 750.0% quarter-over-quarter from $12000.0 in Q3 2025.
Trevi Therapeutics (TRVI) Capital Expenditures (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $102000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $102000.0; the TTM figure through Mar 2026 stood at $121000.0 (changed N/A YoY), while the FY2025 annual figure was $12000.0, down 65.71% from the prior year.
- Capital Expenditures for Q1 2026 stood at $102000.0, up from $12000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $116000.0 in Q4 2022, with the low at $7000.0 in Q4 2024.
- The 5-year median for Capital Expenditures is $31000.0 (2023), against an average of $46750.0.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures tumbled 81.03% in 2023, then sank 68.18% in 2024.
- Trevi Therapeutics' Capital Expenditures stood at $116000.0 in 2022, then sank by 81.03% to $22000.0 in 2023, then slumped by 68.18% to $7000.0 in 2024, then soared by 71.43% to $12000.0 in 2025, then surged by 750.0% to $102000.0 in 2026.
- Business Quant data shows TRVI's Capital Expenditures at $102000.0 in Q1 2026, $12000.0 in Q3 2025, and $7000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 124,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124,000.00 |
| Jun 30, 2026 | 124,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 22,000.00 |
| Dec 31, 2023 | 22,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Jun 30, 2023 | 40,000.00 |
| Jun 30, 2023 | 40,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Dec 31, 2020 | 5,000.00 |